Cheng K, Wang X, Wei X, Ma J, Xia Q Y, Shi Q L, Zhou X J, Rao Q
Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Zhonghua Bing Li Xue Za Zhi. 2020 Nov 8;49(11):1142-1146. doi: 10.3760/cma.j.cn112151-20200224-00127.
To investigate the diagnostic role of NR4A3/NOR-1 immunohistochemistry in acinic cell carcinoma (AciCC) of the salivary gland. A total of 142 tumors were collected from 2004 to 2020 at Nanjing Jinling Hospital, including 24 cases of AciCCs, 12 salivary gland secretory carcinomas,14 salivary duct carcinomas,16 adenoid cystic carcinomas,3 basal cell carcinomas,13 mucoepidermoid carcinomas,7 myoepithelial carcinomas,15 pleomorphic adenomas,15 warthin tumor, 8 myoepithelioma,8 basal cell adenomas, and 7 oncocytomas; 28 normal salivary gland tissues and 2 pancreatic AciCC were also included. NR4A3/NOR-1,a nuclear marker,was positive in 91.7% (22/24) of AciCC of the salivary gland,while DOG1,a membranous and cytoplasmic marker, demonstrated a sensitivity of 95.8% (23/24);there was no significant difference in the overall positive rates(=0.551), but the stain pattern was different. NR4A3/NOR-1 was negative in normal salivary gland tissues and any other types of tumors in the salivary gland; however,DOG1 showed apical staining in the acinar cells in the salivary gland,as well as salivary gland secretory carcinomas,adenoid cystic carcinomas,basal cell carcinomas,mucoepidermoid carcinomas,myoepithelial carcinomas and basal cell adenomas(<0.001). NR4A3/NOR-1 showed a high sensitivity(91.7%) and specificity(100%) to identify AciCC of the salivary gland,and in combination with DOG1, the sensitivity increased to 100%. Furthermore, NR4A3/NOR-1 were only positive for AciCC arising from salivary glands but not pancreas(0/2)(=0.018). NR4A3/NOR-1 is a special and sensitive biomarker for AciCC of salivary glands; combined NR4A3/NOR-1 and DOG1 can be an ideal diagnostic immunohistochemical panel for AciCC.
探讨NR4A3/NOR-1免疫组化在涎腺腺泡细胞癌(AciCC)中的诊断作用。2004年至2020年期间,南京金陵医院共收集了142例肿瘤,其中包括24例AciCC、12例涎腺分泌性癌、14例涎腺导管癌、16例腺样囊性癌、3例基底细胞癌、13例黏液表皮样癌、7例肌上皮癌、15例多形性腺瘤、15例沃辛瘤、8例肌上皮瘤、8例基底细胞腺瘤和7例嗜酸细胞瘤;还纳入了28例正常涎腺组织和2例胰腺AciCC。核标记物NR4A3/NOR-1在91.7%(22/24)的涎腺AciCC中呈阳性,而膜和细胞质标记物DOG1的敏感性为95.8%(23/24);总体阳性率无显著差异(=0.551),但染色模式不同。NR4A3/NOR-1在正常涎腺组织和涎腺的任何其他类型肿瘤中均为阴性;然而,DOG1在涎腺的腺泡细胞以及涎腺分泌性癌、腺样囊性癌、基底细胞癌、黏液表皮样癌、肌上皮癌和基底细胞腺瘤中呈顶端染色(<0.001)。NR4A3/NOR-1对涎腺AciCC具有较高的敏感性(91.7%)和特异性(100%),与DOG1联合使用时,敏感性提高到100%。此外,NR4A3/NOR-1仅对涎腺来源的AciCC呈阳性,而对胰腺来源的AciCC呈阴性(0/2)(=0.018)。NR4A3/NOR-1是涎腺AciCC的一种特殊且敏感的生物标志物;联合使用NR4A3/NOR-1和DOG1可以成为AciCC理想的诊断免疫组化组合。